This makes Ozempic a highly effective therapeutic option for patients managing type 2 diabetes and those working toward sustainable weight loss
The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs
Food and Drug Administration (FDA), the approved dosages for some of the commonly prescribed GLP-1 agonists are as follows: Semaglutide (Ozempic): 0.5 mg, 1 mg, or 2 mg once weekly for type 2 diabetes, and up to 2.4 mg once weekly for chronic weight management (marketed as Wegovy)
The best choice depends on current weight and BMI, weight-related medical conditions, blood sugar status, cardiovascular risk, liver health, kidney function, medication history, side-effect risk, muscle mass and nutrition status, cost and access, patient preference, and long-term maintenance planning
The drug also suppresses inappropriate glucagon secretion
Master protocols to study multiple therapies, multiple diseases, or both